|
¤é´Á |
ºtÁ¿ªÌ |
ÃD¥Ø |
¯Á®Ñ¸¹ |
|
92/01/01 |
¤å¬üëÂå®v |
µÇŦ²¾´Ó¤§¯f²z |
V9201 |
|
92/01/10 |
´^P¤¤Âå®v
¦ó¤WªåÂå®v
ªL©¨¥ÁÂå®v |
¥þ°|Á{§É¯f²z®×¨Ò°Q½×·| |
V9202 |
|
92/01/17 |
ðªÃ½÷Âå®v |
·s¥@¬ö¥Íª«¸ê°T¤Î¦¨ªGµoªí |
V9203 |
|
92/02/21 |
«À¤åÁn¥D¥ô |
¨xŦ²¾´Óªº³Â¾K |
V9204 |
|
92/01/24 |
ªô«n^Âå®v |
¼~Æ{¯gÃĪ«ªvÀøªºÁÍ¶Õ |
V9205 |
|
92/02/21 |
¨H§Ó¶§¦Ñ®v |
¨ÅÀù¤À¤l¾÷Âà¬ã¨s |
V9206 |
|
92/02/28 |
¤ý°ê·Ó±Ð±Â |
The Pathogenesis and Prevention of Steroid Induced Osteonecrosis |
V9207 |
|
92/03/07 |
ù±RªN¥D¥ô |
¹ü°ò¥~¶Ë¤¤¤ß²Ä¤@¦~¦^ÅU»P®i±æ |
V9208 |
|
92/03/21 |
À¹·|ÀsÂå®v
³¯«T¦NÂå®v
¶À°ê°aÂå®v |
¹ü¤Æ°ò·þ±ÐÂå°|¾ÇÄ֨ൣ§¿§É¬ã¨s³ø§i |
V9209 |
|
92/04/18 |
¥ì·J¤åÂå®v |
°|¤º«æ¶E«¯g®ð¹D°V½m¤§¹L¥h»P¥¼¨Ó |
V9210 |
|
92/04/25 |
½²«T©ú±Ð±Â |
Chemtherapy Option for Non-Small Cell Lung Cancer-An Update |
V9211 |
|
92/08/01 |
³¯¶©§Ó±Ð±Â |
¥[¤JÁp¦X°êº[¥xÆW¥¼¨Ó |
V9212 |
|
92/08/08 |
¶À«ØÄÁÂå®v |
Therapectic Roles of ACEIs/ARBs in Renal Paraenchymal Hypertension |
V9213 |
|
92/08/22 |
´¿õ©ú±Ð±Â |
DHEA:¤@ºØ¶¯©Ê²üº¸»XªºÁ{§É·N¸q |
V9214 |
|
92/08/29 |
¤ýÄ_¥Ð±Ð±Â |
ÀWÃЦ¡¦h¦â®Ö§Î¤ÀªR(SKY)¤§Á{§ÉÀ³¥Î |
V9215 |
|
92/09/19 |
Carlos M. Forraio Ph.D. |
The promise of losartan in cavdiovascular disease a vurrent pevs pective |
V9216 |
|
92/09/26 |
´öÂ׸ÛÂå®v |
Occupational health of chromium plating workers |
V9217 |
|
92/10/03 |
David Norman Sharpe |
Translation of clinical Trial Evidence into Practice:Specific lssues and Barriers to Treatment |
V9218 |
|
92/10/31 |
³¯§ÓÂEÂå®v |
Evolving Concepts in the Management of Chronic Heart Failure |
V9219 |
|
92/11/07 |
¤ý§®´D³Õ¤h |
±q°ò¦Âå¾Ç¨ìÁ{§É¤WªºÀ³¥Î:Treatment
of SMA |
V9220 |
|
92/11/14 |
ù±R³Ç¥D¥ô |
Systemic inflammatory response following trauma and surgery:from bench to bedside |
V9221 |
|
92/12/05 |
³¯ºaºÖÂå®v |
New Uista of Osteoporosis Treatment A Clinical update of Evista and Forteo |
V9222 |
|
92/12/12 |
ªL·ç²»°Æ°|ªø |
·L¶q¥Õ³J¥Õ§¿Microalbuminuria |
V9223 |
|
92/12/26 |
§õ´f¤¯Âå®v |
Advance imaging diagnosis for Brain tumors |
V9224 |
|
93/01/16 |
ªLõ¶¯Âå®v |
¥xÆWÂå®v¹ï¥xÆW¤å¤Æªº°^Äm |
V9301 |
|
93/02/06 |
¼B«C¤s°Æ¥D¥ô |
Methleneterahydrofolate Reductase °ò¦]¦h«¬©Ê |
V9302 |
|
93/02/13 |
¼BÀé§»¡B§d¦Ü¦æÂå®v |
Âå°|¸gÀç´î«¸gÅç½Í |
V9303 |
|
93/02/27 |
¿½¬üµ^ | §Ú°ê¦b°ê»Úªº³B¹Ò | V9304 |
|
93/03/05 |
§õ½å¶¯¬ã¨sû | The CYP21 in congenital adrenal hyperlasia | V9305 |
| 93/03/12 | ¬x¦¨§ÓÂå®v | ±ßµo«¬¿ò¶Ç¯e¯fªº¶EÂ_»P¿Ô¸ß | V9306 |
| 93/03/19 | ³³ªüÛ¥D¥ô | ¥þ°ê«~½è«ü¼Ð¡]TQIP¡BTHIS¡^¢w¹ü°ò¦¨ªG³ø§i | V9307 |
| 93/03/26 | §õ´f¤¯Âå®v | CNS infection: update- | V9308 |
| 93/04/09 | ¨H»ÊÃè±Ð±Â | §Ü¾®¦å»s¾¯¤§¨Ï¥Î | V9309 |
| 93/04/16 | Pierre Amarenco, M.D. | Sratins Stroke Prevention: after ASCOT positive resulrs. Hope for SPARCL | V9310 |
| 93/04/23 | Á§³Õ¤¯Âå®v | Infection pneumoncoccus disease in Taiwan¡]ªþÁ¿¸q¡^ | V9311 |
| 93/04/30 | ¹ù´Â±]±Ð±Â | The Role of Diuretics in Hypertension Treatment | V9312 |
| 93/05/07 | ¬x«a¤©¥D¥ô | Cardio-renal protection | V9313 |
| 93/05/14 | ¨H»ÊÃè±Ð±Â | Venous Thrombophilia in Taiwan | V9314 |
| 93/05/28 | ³¯©vÃs°Æ°|ªø | This is other kind of it, Hope you'll enjoy it too !!- The Losartan Intervention For Endpoint Reduction in Hypertension Study | V9315 |
| 93/06/11 | ³¢¾ð¥Á±Ð±Â | Current trends in congenital heart surgery | V9315 |
| 93/06/18 | ¥ÕªG¯à³Õ¤h | Promises and challenges to the emerging biochip technologies | V9316 |
| 93/07/09 | «J®¶®õÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9317 |
| 93/07/16 | Á¬Fõ³Õ¤h | The Molecular Basis of Glycogen Storage Disease Type la: Structure and Function Analysis of Mutations in Glucose- 6- Phosphatase | V9318 |
| 93/07/23 | Tom Linson, P.D. | Primary and Secondary Prevention of Stroke..Advantages of Ramipril - Dased Therapy | V9319 |
| 93/07/30 | ¨H»ÊÃè±Ð±Â | New advances in disseminated intravascular coagulation¡]´²¼½©Ê¦åºÞ¤º¾®¦å¯gªº·s¶i®i¡^ | V9320 |
| 93/08/06 | ³\¥Ã²»¥D¥ô | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9321 |
| 93/08/20 | ¤ý¤ô²`±Ð±Â | Treatment of peripheral arterial occllusive disease | V9322 |
| 93/08/27 | ´å¯à«TÂå®v | Optimize insulin therapy | V9323 |
| 93/09/10 | ³¯¹F¤H±Ð±Â | ±q¨Å©Ð¶Wµªi½Í¬ã¨sÂI¤lªº²£¥Í | V9324 |
| 93/09/17 | ¦¿ºÖ¥Ð±Ð±Â | The Evolution of RAS Blockade- High-Risk Hypertension Management along the Cardiovascular Continuum | V9325 |
| 93/09/24 | ³¯ºaºÖ¥D¥ô | New frontier management in Diabetic Nephropathy | V9326 |
| 93/10/01 | ³¯«Û¦tÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9327 |
| 93/10/08 | ©P±Ò¤å¥D¥ô | Æ`¤º°Ê¯ß½F¯}µõ±wªÌ¦å¼ßºû¥Í¯ÀC¡Bºû¥Í¯ÀE¯×½è¹L®ñ¤Æ¤ÏÀ³¤§ÅÜ¤ÆÆ[¹î | V9328 |
| 93/10/15 | §õ¦t©zÂå®v | ¡uºÎ¯v¯Ê·l»P²M¿ô°IºÜ¡v(Sleep Insufficiency and Impaired Alertness) | V9329 |
| 93/10/22 | Professor of Medicine Mt Sinai School of Medicine New York Medicine Sol Epstein MD | Treatment of Osteoporosis: A comprehensive review from a bone strengh perspective fetal therapy hydrops fetalis and oligohydramnios | V9330 |
| 93/10/29 | ªLõ¨k±Ð±Â | Anorectal Malformations | V9331 |
| 93/11/05 | ¤ý¦Ë½åÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9332 |
| 93/11/12 | M. London | A Global Approach to Hypertension its Cardiovascular Complication-Gerard | V9333 |
| 93/11/19 | ¶À®õµM³Õ¤h | ³Ì·sBiomarker¤§¬ã¨s»Pµo®i | V9334 |
| 93/11/26 | ³¯©úÂå®v | Invasive fetal therapy hydrops fetalis and oligohydramnios | V9335 |
| 93/12/03 | §dµOÖHÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9336 |
| 93/12/10 | §ù«ä¼wÂå®v | Metabolic Syndrome | V9337 |
| 93/12/17 | Á§³Õ¤¯Âå®v | °|¤ºMRSA·P¬V | V9338 |
| 93/12/24 | ³¯©y§gÂå®v | «Iŧ©ÊÅðµß·P¬VªvÀø·sª¾ | V9339 |
| 93/12/31 | ®]®a´ÉÂå®v | ¦º¤`µý©ú®Ñªº¶}¨ã | V9340 |
| 93/12/18 | ³\l©ú³Õ¤h | ¯S§OºtÁ¿Comparison of two decoy therapeutics for BAFF, a B cell activating factor belonging to the TNF family. | V9341 |
| 94/01/14 | ¦DºÖ¬hÂå®v | ¨xŦ¯f²z¦b¨xŦ²¾´Óªº¨¤¦â | V9401 |
| 94/01/28 | ®]®a´ÉÂå®v | ¥Õ¦â¥¨¶ðªº±Òµo¢wÂåÀøªÈ¯É±±Æ[ | V9402 |
| 94/02/04 | ³\¥Ã²»¥D¥ô | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9403 |
| 94/02/18 | ªL·ç²»±Ð±Â | Initiation and Usage of Insulin·sªºªø®Ä¯Ø®q¯ÀGlargine | V9404 |
| 94/02/19 | ³¯¼[¤¯²Õªø | 94¦~Âå°|Á`ÃB¹wºâºÞ²z | V9405 |
| 94/02/25 | ³¯©÷¥°Æ±Ð±Â | °ò¦]§ÜÅé»P¦å²M³J¥Õ¤ÀÂ÷ªºÀ³¥Î | V9406 |
| 94/03/04 | ªL§Ó¦¨½Òªøµ¥ | ¨È¤ÓÂå¾Ç½×¾Â³Ì·sµo®iªñªp¢w2004¦~FERCAP¦~·|ªð°|³ø§i | V9407 |
| 94/03/11 | ¤è²`¼Ý±Ð±Â | ¹L±Ó©Ê»óª¢¶EÂ_»PªvÀø | V9408 |
| 94/03/18 | ¤ý¥þ¥¿Âå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9409 |
| 94/03/22 | Michael Beez | Pathophysiology, monitoring and therapy of shock with organ failure | V9410 |
| 94/03/25 | ³¯§ÓÂE°|ªø | Preventing Strategies for Vascular Disease-targeting endothelial dysfunction | V9411 |
| 94/04/01 | ³¯¬L¨}Âå®v | Non-Invasive Advanced Airway Management | V9412 |
| 94/04/08 | ¬_¦¨°ê±Ð±Â | ¬ã¨s¤Î±Ð¾ÇªºÂå°|¤å¤Æ | V9413 |
| 94/04/15 | ¿ÛÂE»·§U²z±Ð±Â | ¤À¤l¼Ð¹v®ÖºØªvÀø¨ÒÃÒ¡G¶u¸K¦@¸üÅé´C¤¶©ñ¸KªvÀø©ó¤À¤Æ¥Òª¬¸¢Àù¤§À³¥Î | V9414 |
| 94/04/29 | ´¿¦p²WÂå®v | °ª¦åÀ£¤§¤£¯à©¿²¤ªºªvÀø¥Ø¼Ð¢w°§C²M±á¦åÀ£ÆJ¤É | V9415 |
| 94/05/06 | ³¯¬v·½Âå®v | Âù®ðÅn¤p¸zÃèÀˬd | V9416 |
| 94/05/13 | §ù«ä¼wÂå®v | ¿}§¿¯f»P¶gÃä¦åºÞ¯e¯f¶EÂ_»P³B²z | V9417 |
| 94/05/27 | ½²¥@¿AÂå®v | ¿}§¿¯fÃĪ«ªvÀøªº·sÁÍ¶Õ | V9418 |
| 94/06/03 | ¤_®¶ªFÂå®v | Management of Knee Joint Osteoarthritis | V9419 |
| 94/06/10 | ³¯§g¨Ô±Ð±Â | Corneal Epithelial Stem Cell and Its Clinical Application | V9420 |
| 94/06/17 | ·¨¯ª¥ú¥D¥ô | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9421 |
| 94/06/24 | Prof. Philip Barter | New Challenge, New Standard, New Satin | V9422 |
| 94/07/01 | ³\¥Ã²»¥D¥ô | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9423 |
| 94/07/08 | ®]®a´ÉÂå®v | §ä¦^«æ¶E«Çªº¬K¤Ñ | V9424 |
| 94/07/15 | Á®a©úÂå®v | ¥¿¤l¹q¸£Â_¼h¡]PET/CT¡^¤§Á{§ÉÀ³¥Î | V9425 |
| 94/07/22 | ¼B«C¤s¥D¥ô | 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢wmitochondrial disease | V9426 |
| 94/07/29 | ³¯¦Û½ÌÂå®v | Application of Laparoscopy in Colon and Rectal Cancer Surgery | V9427 |
| 94/08/05 | Á©ӾëÂå®v | ¹ï°ªÀ£®ñªvÀøªº»{ÃÑ | V9428 |
| 94/08/12 | Dr. Michael L. Leski | ^¤å½×¤å¼g§@ | V9429 |
| 94/08/19 | ¤ý°êºÕ±Ð±Â | ©`¦Ì¥ÍÂå | V9430 |
| 94/08/26 | Socrates E Papapoubs Pro | Developm ent in Bisphosphonate Therapy in Osteoporosis Facts, Questions and Fiction | V9431 |
| 94/09/02 | ù¼z¬Ã³Õ¤h¡F§d«H§»Âå®v | 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢w1.¥H°Êª«¹êÅç¤Î¤HÅé¸ÕÅç¶i¦æÀç¾i¬ÛÃö¬ã¨s¤§¸gÅç¤À¨É¡F2.Á{§ÉÂå®v»P°ò¦¬ã¨s | V9432 |
| 94/09/16 | ¶À³Ó½åÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9433 |
| 94/09/23 | ªL²M²W°|ªø | 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢w¥ÀÅé°ª¦å¿}¹ïL¨àµÇŦµo¨|ªº¼vÅT | V9434 |
| 94/09/30 | ¬_¤åõ±Ð±Â | ¥~¬ì³N«á·ÓÅ@¡]Post-op care in severe IA¡^ | V9435 |
| 94/10/07 | ·Å¥Ã¹|Âå®v | ºÎ¯vÂå¾Çªº·sµo®i | V9436 |
| 94/10/14 | ªLõ¨kÂå®v | ·Rªº¦A³y½Í°_ | V9437 |
| 94/10/21 | §õ´f¤¯Âå®v | Low Back Pain | V9438 |
| 94/10/28 | S¬u¤sÂå®v¡F·¨¤O¿ÅÂå®v | ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q | V9439 |
| 94/11/04 | ¤ý¤h©¾Âå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9440 |
| 94/11/11 | ³¯¾_¾È±Ð±Â | Assessment of Ventriculo-arterial Coupling by Automated Systolic Time Intervals | V9441 |
| 94/11/18 | ªL¥@ÅMÂå®v | Continuous Glucose Monitoring System | V9442 |
| 94/11/25 | Prof. Wolfgang. Eisert | Antithrombotic treatment of the vessel wall?--rather than antiplatelet or anticoagulant therapy | V9443 |
| 94/12/02 | ÃQÄ£´§±Ð±Â | 1.¦p¦ó¼¶¼g½×¤å¤Î¬ã¨spµe¡F2.¦p¦ó¥Ó½Ð°ê®a«¬pµe | V9444 |
| 94/12/09 | prof. Ronald F. Grossman | Initial management of Patient with Community-acquired Pneumo | V9445 |
| 94/12/16 | ªL©¯¹D°Æ®Õªø | ¨ÅÀù³N«á¥ß§Y¨Å©Ð««Ø | V9446 |
| 94/12/23 | ¨H©úÃè±Ð±Â¡FĬõ«T¥D¥ô | 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢w1.A.¥xÆWÃþ¦å¤Í¯fªº¬ã¨s¢wªì³ø¡AB.¹ü°ò°©Åè¼W´Þ¯gªº¬ã¨s¡F2.»{Ãѹü¤Æ¢w¤fµÄÀùÆ[ÂI¡C | V9447 |
| 94/12/30 | ®]®a´ÉÂå®v | «æ¶E«Ç¤º¹ï¥æ³q¨Æ¬Gªº»{ª¾ | V9448 |
| 95/01/06 | ³¯©úÂå®v | 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢wExplore the Frontier of Fetal Medicine and Clinical Genetics:from risky novel clinical therapy to benchwork94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢wExplore the Frontier of Fetal Medicine and Clinical Genetics:from risky novel clinical therapy to benchwork | V9501 |
| 95/01/13 | Joseph A. Paladino Professor | Major Treatment guideline of hospital -- acquired Pneumonia-- an Overview and Outlook | V9502 |
| 95/01/20 | ¿½´I·½Âå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9503 |
| 95/02/03 | ³\¤W¤HÂå®v | ¯f¾ú¼g§@ | V9504 |
| 95/02/10 | ´¿©À¥ÍÂå®v | Palliative medicine treatment of depression in the medically ill | V9505 |
| 95/02/17 | ³¯¨j¦{±Ð±Â | ·F²ÓM¬ã¨sªº°g«ä»P¼ç¤O | V9506 |
| 95/02/24 | ³¯ºaºÖ¥D¥ô | New Vista of Osteoporsis Treatment | V9507 |
| 95/03/03 | ³\¥Ã²»¥D¥ô | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9508 |
| 95/03/10 | Melody H. Lin | Human Subjects Protections in Clinical ResearchRoles & Responsibilities | V9509 |
| 95/03/17 | Dr. Han-Mou Tsai | Recent Advances in the Diagnosis and Treatment of TTP | V9510 |
| 95/03/24 | ¦¿±á®¦±Ð±Â | Beta-Blocker¦b¤ß°IºÜªºªvÀø | V9511 |
| 95/03/31 | ³¯«T¦NÂå®v¡F±i¶iÄ_¥D¥ôµ¥ | ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q | V9512 |
| 95/04/07 | §ù«ä¼w°|ªø | The rational use of prandial glucose regulator in hospital | V9513 |
| 95/04/11 | ¶À¸Î´Ü±Ð±Â | Update on the Management of Sepsis: An Evidence-Based Approach -- ±Ñ¦å¯gªvÀø¤§³Ì·s¹êÃÒ | V9514 |
| 95/04/14 | Á¬Fõ³Õ¤h | 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C¢w¤HÃþ¸²µå¿}¤§ÁC»Ä酶b¥½ºÝµ²ºc¹ï¨ä³J¥Õéw©Ê¤ÎÁC»Ä¤ô¸Ñ¬¡©Ê¤§¼vÅT | V9515 |
| 95/04/21 | ±i¥¿¶¯°Æ°|ªø | ¦p¦ó§iª¾t±ªº®ø®§ | V9516 |
| 95/04/28 | ¤ý°ê·Ó®Õªø | Effects of Anti-inflammatory Drugs on Osteogenic Cells | V9517 |
| 95/05/05 | ³\·ç©÷Âå®v¡F·¨¯\µÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9518 |
| 95/05/12 | ªL§»¹F±Ð±Â | Fasping or Postprandial Glycemia, What Matters Most ? | V9519 |
| 95/05/19 | ¤ý°ê¶§¥D¥ô | Pharmacotherapy in Atherothermbosis | V9520 |
| 95/05/26 | ¥ÕªG¯à³Õ¤h | Circulating tumor cell detection and its applications in lung cancer studies(ªÍÀù²ÓM¦b¦å²G´`Àô¤¤ªº°»´ú¤Î¨äÁ{§ÉÀ³¥Î) | V9521 |
| 95/06/02 | §ÅÁíÀM¥D¥ô | Surgical treatment in parkinson,s disease | V9522 |
| 95/06/09 | Áé´¼²W¥D¥ô | Introduction of blood component therapy | V9523 |
| 95/06/16 | ·Å¤¯©MÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9524 |
| 95/06/23 | ªL¦P´ËÂå®v | 94¦~«×±Ð¬ã¦¨ªG³ø§i¨t¦C-AN ASSOCIATION OF DNMT3b PROTEIN EXPRESSION WITH P16INK4a PROMOTER HYPERMETHYLATION IN NON-SMOKING FEMALE LUNG CANCER WITH HUMAN PAPILLOMAVIRUS INFECTION¤Î±qÁ{§É¨ì°ò¦¬ã¨s¤§¤ß¸ô¾úµ{ | V9525 |
| 95/06/30 | ¸§»¤@Âå®v | Cardiovascular Protective Effects¡GThe Role of ARBs | V9526 |
| 95/07/07 | ¼B«C¤s¥D¥ô | ¿ò¶ÇÛ²z:±q»RÁЯg»P¤p¸£µäÁY¯g½Í°_ | V9527 |
| 95/07/21 | §õªFª¢Âå®v¡F³¯³ó«WÂå¥D¥ô | ÂåÀø«~½è§ïµ½®×¨Ò¬ã°Q | V9528 |
| 95/07/28 | ³\¥Ã²»¥D¥ô | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9529 |
| 95/08/04 | »¯¹ÅÛÂå®v | The Role of AntiPlatelte in Athorothrombosis | V9530 |
| 95/08/11 | ³¯ºaºÖ¥D¥ô | Oxidant stress & Diabetes complication | V9531 |
| 95/08/18 | ·¨¤O¿Å°|ªø | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9532 |
| 95/08/25 | S¸t¿³°Æ±Ð±Â | ¥HªGÃǬã¨s¤HÃþªº¯e¯f¡A¥i¯à¶Ü¡H | V9533 |
| 95/09/01 | §õ§B¼ý±Ð±Â | ¦¨¤jÂå°|±À°Ê¾¹®½Á~¶Ç¥Í©Rªº²z©À»P§@ªk | V9534 |
| 95/09/08 | ³\¤W¤HÂå®v | ¯f¾ú¼g§@ | V9535 |
| 95/09/15 | James Kuang- Jan Liao Prof. | Are All Statins The Same ? | V9536 |
| 95/09/22 | William L. Nyhan, Ph.D. | Maple Syrup Urine disease/Liver Transplant | V9537 |
| 95/09/29 | ±iÑÔº³Âå®v¡F³¢¾ð¥Á±Ð±Â | ÂåÀø«~½è§ïµ½®×¨Ò¬ã°Q | V9538 |
| 95/10/13 | ªL¥@ÅMÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9539 |
| 95/10/20 | Á«ä¥ÁÂå®v | Management of Hospital-acquired Pneumonia and the Role of Fluoroquinolones | V9540 |
| 95/10/27 | Toronto General Hospital Peter P. Liu | Halting the Progression from Post-MI to Heart Failure. | V9541 |
| 95/11/03 | ±i«Ø°ê°Æ°|ªø | Modulating the alternative splicing of exon 7 of SMN gene by drugs. | V9542 |
| 95/11/10 | ±ç¤å±Ó°Æ±Ð±Â | °ÝÃD¾É¦Vªº²Îp¤ÀªR | V9543 |
| 95/11/17 | ³\´f«í±Ð±Â | Insulin reseielance oxidative stree and cardiovasculor disease | V9544 |
| 95/11/24 | À¹¼zÀsÂå®vµ¥ | ÂåÀø«~½è§ïµ½®×¨Ò¬ã°Q | V9545 |
| 95/12/01 | ¾G´J¤¯Âå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9546 |
| 95/12/08 | Pro.Marc De Broe | New insight into the mechanism of nephrolithesis. | V9547 |
| 95/12/15 | ©PªQ¨k±Ð±Â | Vaccine Against Cervical Cancer: A Breakthrough in 21st Century¡]¤G¤Q¤@¥@¬öÂå¾Ç¤j¬ð¯}¡G¹ï§Ü¤l®cÀVÀùªº¬Ì]µo©ú¡^ | V9548 |
| 95/12/22 | ³¯¥þ¤ì±Ð±Â | DNA¥Ò°ò¤Æ°ò¦]´¹¤ù¤§¬ãµo¤Î¨äÀ³¥Î©ó¸ÑºcÀù¯g¤§¡§¤W¿ò¶Ç©Ê¡¨Åܲ§ | V9549 |
| 95/12/29 | ¥Û©ú·×°Æ°|ªø | History of Artificial Airways | V9550 |
| 96/01/05 | ¿½©sªÚ±Ð±Â | ½E¬Ì¾y¼v | V9601 |
| 96/01/12 | ±iª÷°í±Ð±Â | ¦]À³°ª¬ì§ÞÂåÀø¤§·sÛ²zÆ[ | V9602 |
| 96/01/19 | ¬x°·²MÂå®v | µg¯eªü¦Ì¤Úì¦ä·P¬V»P·R´þ¯f¬r·P¬V | V9603 |
| 96/02/02 | ±iª÷°í±Ð±Â | ¦åºÞ·s¥Í»PÀù¯g | V9604 |
| 96/02/09 | ³\¥Ã²»¥D¥ô | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9605 |
| 96/03/02 | ùºúÁ¾¥D¥ô | ¨D¤¤¤§Âå | V9606 |
| 96/03/09 | Pro. Paul Richard Conlin | The benefical effects of mono and combination AllA thrapy to lower blood pressure for diabetes patients | V9607 |
| 96/03/16 | Pro. Andrew M. Tonkin | Lipids-who, why and how to treat? Targets are important | V9608 |
| 96/03/23 | ªL¥È«ßÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9609 |
| 96/03/30 | ³¯¨qº³±Ð±Â | ¨ÅÀù¦h«°»´ú¤èªk»P¯e¯f¦ÛµM¥v | V9610 |
| 96/04/06 | ªLºû¬wÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9611 |
| 96/04/13 | ³¯ºaºÖ¥D¥ô | Statin- The Role Between the Kidney & Heart | V9612 |
| 96/04/20 | ·¨§Âå®v | ÂåÀø«~½è§ïµ½®×¨Ò¬ã°Q | V9613 |
| 96/04/27 | ¿à౹ťD¥ô | Medical Teaching through PBL+EBM | V9615 |
| 96/05/11 | ³¯°öõ°|¤h | Major Liver Diseases in Taiwan: From Hepatitis B to Others. | V9616 |
| 96/05/18 | ªô¬±ªÚÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9617 |
| 96/05/25 | «J©ú¾W±Ð±Â | ¨ÅÀù¥~¬ìªvÀøªº¹L¥h¡B²{¦b¡B¥¼¨Ó | V9618 |
| 96/06/01 | §õ¥ú¥ÓÂå®v | Mesenchymal Stem Cells: An Update | V9619 |
| 96/06/08 | ³¯©úÂå®v | ¿ò¶Ç¾Ç¬ã¨s¤èªkºî¡GÁ{§ÉÂå®v¦p¦ó»P¿ò¶Ç¾Ç®a·¾³q | V9620 |
| 96/06/15 | ·¨´¼¥þÂå®v | ÂåÀø«~½è§ïµ½®×¨Ò¬ã°Q | V9621 |
| 96/06/22 | §d©ú¾§¥D¥ô | Management of CKD | V9622 |
| 96/06/29 | Á©ú®a¥D¥ô | The risk factors for corony artery disease and nephropathy in Chinese with type 2 diabetes | V9623 |
| 96/07/06 | ³\¥Ã²»¥D¥ô | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9624 |
| 96/07/13 | ªL¥Ãõ±Ð±Â | ¦Ñ®v±Ð»£ | V9625 |
| 96/07/20 | §õ¤ë§g±Ð±Â | Analyzing genomic alterations in human glioma cells by molecular cytogenetics | V9626 |
| 96/08/03 | ¤ý¥þ¥¿Âå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9628 |
| 96/08/10 | §ù«ä¼w°|ªø | ¨È¬w²Ä2«¬¿}§¿¯f¨Ö¦³©PÃä°Ê¯ß¯e¯fªº²±¦æ²v»PÁ{§Éªí¼x¤§¦h°ê¬ã¨s | V9629 |
| 96/08/17 | ³¯ÂE¾_±Ð±Â | ¦p¦óÁ×§K¤£·íªº¼Æ¾Ú³B²z¡]How to avoid inappropriate data processing¡^ | V9630 |
| 96/08/24 | §d¦Ü¦æÂå®v | Awareness and Knowledge of Osteoporosis in Taiwan | V9631 |
| 96/08/31 | ³¯³ó«W¥D¥ô | Liver transplantation in CCH | V9632 |
| 96/09/07 | Szilard Voros MD. | The Role of Lipoproteins Atherogenesis | V9633 |
| 96/09/14 | §õ½÷±Ð±Â | Environmental Exposure and Lung Cancer | V9634 |
| 96/09/21 | Dr. Bjorn Dahlof | JIKEI Heart Study: How can we improve outcome in Asian patients? | V9635 |
| 96/09/28 | §ÅÁíÀM¥D¥ô | ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q | V9636 |
| 96/10/05 | ¾G¶®¤å°Æ±Ð±Â | Human Papillomavirus 16/18 E6 Oncoprotein is Expressed in Lung Cancer and Related with P53 Inactivation | V9637 |
| 96/10/26 | ½²¹FªQ¥D¥ô | °ª¦MÀI¯f±wÀR¯ß®ê¶ë¤§³Ì¨Î¹w¨¾ | V9640 |
| 96/11/02 | ¬I¿o»ÊÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9641 |
| 96/11/09 | ·¨¤å¥ú±Ð±Â | ´c©Ê¸£½F¤§¾ð¬ð²ÓM¸~½F¬Ì]ªvÀø¡GÁ{§É¸ÕÅç»P¨ä«á¤§ÂàĶÂå¾Ç¬ã¨s | V9642 |
| 96/11/16 | ³\ªÃ¹ç©Òªø | Role of chemokine receptor CCR6 in induction of gastric inflammation during Helicobacter infection | V9643 |
| 96/11/23 | ³¯©÷©úÂå®v | Better stroke prevention : The role of ARBs | V9644 |
| 96/11/30 | ¾G§¡¬§Âå®v | ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q | V9645 |
| 96/12/07 | ¦¿±á®¦±Ð±Â | ¦å¯×ªvÀø·s²z©À | V9646 |
| 96/12/14 | PhD James Shepherd | Safe and effective treatment for diabetic dyslipidaemia | V9647 |
| 96/12/21 | ³¯Ãý¤§Âå®v | ºÎ¯v©I§l¤¤¤î¯g | V9648 |
| 96/12/28 | ¸§»¤@°Æ¥D¥ô | Lipid Management 2007--Where do we stand? | V9649 |
| 97/01/04 | ¶À¥ü¤s¥D¥ô | ¦~«×©ÊÀR¯ßª`®gÂùÁC»ÄÆQ¦b°©ÃPªvÀø¤Wªº·s¶i®i | V9700 |
| 97/01/11 | ½²¬F¾Ë¸³¨Æªø | ·F²ÓM¬ãµo | V9701 |
| 97/01/18 | ªL¤¤¥Í±Ð±Â | ¤ß°IºÜªvÀø--¤µ©õÆ[©Àªº®t²§ | V9702 |
| 97/02/01 | ³¯«Tºa°Æ°|ªø | ±q¤¤·¨¾ªv¨ì¾ã¦X©Êªº·ÓÅ@¨t²Î | V9704 |
| 97/02/15 | ªL·ç²»±Ð±Â | ¿}§¿¯f·sª¾¢w1.ATP±Ó·P©Ê¹[Â÷¤l³q¹D¤Î·s¥Í¨à¿}§¿¯f¡F2.GIP, GLI-1»PExenatide | V9705 |
| 97/02/22 | ³\¤W¤HÂå®v | 97¦~²Ä¤@³õ¡u¯f¾ú¼g§@±Ð¾Ç¡v¬ã²ß·| | V9706 |
| 97/02/29 | ¶À±i±ù§g±Ð±Â | Utility of oligonucleotide array-base comparative genomic hybridization for detection of intragenic deletions | V9707 |
| 97/03/07 | ªL´Ü¶í±Ð±Â | Nasopharyngeal carcinoma: molecular pathogenesis, gene expression profiling and clinical intervention | V9708 |
| 97/03/14 | Prof. Rick Adachi | Bone Formation Agent for Severe Osteoporosis Management | V9709 |
| 97/03/28 | ªô§Ó¤åÂå®v | ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q | V9711 |
| 97/04/11 | ªLõ¨k±Ð±Â | «÷¹Ï¤H-¨xŦ²¾´Ó¥ýÅX ¥v¹Fµ¦Âå¥Í¶Ç°O | V9712 |
| 97/04/18 | §õÌɾËÂå®v | Current surgical treatment for morbid obesity | V9713 |
| 97/04/25 | ±i¤¤©M¬ã¨sû | ging,reactive oxygenoxygen species and advancedglycation end products(ages) | V9714 |
| 97/05/02 | ½²«C¶§¥D¥ô | ¨Åé»P¤ßÆFªº¸Ñå | V9715 |
| 97/05/09 | ªô¼ü©úÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9716 |
| 97/05/16 | ¦¿±á®¦±Ð±Â | Treatment of hypertension: where do we stand in 2008? | V9717 |
| 97/05/30 | ³¯¾å¯àÂå®v | ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q | V9719 |
| 97/06/06 | ¤ý´_¼w¥D¥ô | ²Äõ¤ó¶§©Êµß·P¬VªºªvÀø | V9720 |
| 97/06/13 | ©P¤ÖµØÂå®v | ÂåÀø±¡¹Ò¤¤¨â©ÊÃö«Y | V9721 |
| 97/06/20 | ¬I¹Å©M±Ð±Â | Maturation and virion release of human hepatits b virus variants | V9722 |
| 97/06/27 | ®]®a´É±Ð±Â | ·í¹J¨ìÂåÀøªÈ¯É®É Âå°|¦p¦ó³B¸m | V9723 |
| 97/07/04 | ªL©¯ºa¥D¥ô | ¤ßŦ°IºÜªº³Ì·sªvÀø | V9724 |
| 97/07/18 | §º¥Ã»í°Æ°|ªø | Update management of osteporosis | V9726 |
| 97/07/25 | ®]³¹ðÂå®v | ÃEÃC±·î«¬¤Î¾¦¦C«r¦X¤£¥¿¤§ªvÀø | V9727 |
| 97/08/01 | ªL§µ¸qÁ{§É±Ð±Â | ·Àã¯f¶EÂ_¤ÎªvÀøªºÂÕ«ä | V9728 |
| 97/08/08 | ³¯³s¥ÍÂå®v | §U²£³Nmidwiferyªº¾ú¥v | V9729 |
| 97/08/15 | ³¯¹F¤H±Ð±Â | 96¦~«×¬ã¨s¦¨ªG³ø§i¨t¦C¡]¤@¡^Àù¯gÂå¾Ç¬ã¨s«Ç¦~«×¦¨ªG³ø§i°ò¦¬ã¨s¨ìÁ{§É¹w¨¾Âå¾ÇÀ³¥Î | V9730 |
| 97/08/20 | ³\¤W¤HÂå®v | 97¦~²Ä2³õ ¯f¾ú¼g§@±Ð¾Ç ¬ã²ß·| | V9731 |
| 97/09/05 | ½²¬F§»Âå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9733 |
| 97/09/26 | ªLªFÀé¥D¥ô | Leukocyte-depleted component therapy¡]´î°£¥Õ¦å²y«~¤§À³¥Î¡^ | V9735 |
| 97/10/17 | ¤ý¤h©¾Âå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9737 |
| 97/10/24 | Lansberg, Peter Jan | Vascular imaging for evaluating CHD risk and treatment assessment | V9738 |
| 97/10/31 | ³¯ºaºÖ¥D¥ô | "Bone appetit" foundation of bone health | V9739 |
| 97/11/07 | §d¤ìºaÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·|¢wÂåÀøªÈ¯É¤§¯f²z¾÷Âà¡]The pathogenesis of medical malpractice¡^ | V9740 |
| 97/11/14 | Ĭ¥Ú¥ßÂå®v¡F©P¤ÖµØÂå®v |
96¦~«×¬ã¨s¦¨ªG³ø§i¨t¦C¡]¤T¡^¡G(1)Mitochondrial DNA 16189t to c variant in patients with
type 2 diabetes combined peripheral arterial disease¡F (2)²É½uÅé¥\¯à»Ùê»Pºë¯«¯e¯f |
V9741 |
| 97/11/21 | ½²ÂE¼w¥D¥ô | 96¦~«×¬ã¨s¦¨ªG³ø§i¨t¦C¡]¥|¡^¡G¥Í´ÞÂå¾Ç¬ã¨s«Ç¬ã¨s¦¨ªG¤¶²Ð | V9742 |
| 98/01/02 | ©P¦¼¤t¸³¨Æªø | ½Í¾i¥Í | V9800 |
| 98/01/09 | §ù«ä¼w°|ªø | ¥NÁ¯gÔ¸s¤Î¿}§¿¯f±wªÌ¦å¯×²§±`ªvÀø¤§·s¥D±i | V9801 |
| 98/01/16 | ´¿±Ò·ç°|ªø | Á{§ÉÂå®v¦p¦ó±q¨ÆÂàͬã¨s¡]How to apply trans lational research in clinical medicine¡^ | V9802 |
| 98/01/23 | ªL·U³¨Âå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9803 |
| 98/01/30 | ¿ú«Ø¤åÂå®v | ÂåÀø»P¡§©Ê§O¥D¬y¤Æ¡¨ | V9804 |
| 98/02/06 | ¼B«C¤s°Æ°|ªøµ¥ | (ACGME)¦í°|Âå®v¤»¤j®Ö¤ß¯à¤O±Ð¾Ç | V9805 |
| 98/02/13 | ¤ý´_¼w¥D¥ô | Âå¾Ç¤H¤å¡AÛ²zªk«ß¡A¥þ¤HÂåÀø¨â©ÊijÃD»P·P±± | V9806 |
| 98/02/20 | ³¢³Õ¬L±Ð±Â | ¥Í²z«ß°Ê¤ÀªR¨t²Î¤§¬ãµoÀ³¥Î¤Î¥¼¨Ó®i±æ | V9807 |
| 98/03/06 | §d¤ìºaÂå®v | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·|¢wÂåÀøªÈ¯É»PªkÂå¸Ñå | V9809 |
| 98/03/13 | ¶À«T¶¯Âå®v | 2009¦~²Ä¤@³õ¡u¯f¾ú¼g§@±Ð¾Ç¡v | V9810 |
| 98/03/20 | Lawrence A. Leiter Professor | Inflammation in Atherosclerosis Is it clinically important? Results of recent clinical trials | V9811 |
| 98/03/27 | ±i§»°ò¥D¥ô | ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q | V9812 |
| 98/03/27 | ¦¿¦Û±o¥D¥ô | ¸Ö¡BÂå¾Ç¡B¥xÆW | V9813 |
| 98/04/03 | ¼B«C¤s°Æ°|ªø | ¦åºÞº[°ò¦]Åé¬ã¨s¤¤¤ß2009¦~¦¨ªGµoªí·| | V9814 |
| 98/04/17 | Asprer Jonathan Pro. | Immunomodulation by nutrition therapy surgery and critical illness. | V9816 |
| 98/04/24 | ¬I´º¤¤Âå®v | Placenta accreta in the 21th century the new horizon with 3D power doppler and temporally balloon occlusion of CIA | V9817 |
| 98/05/01 | Kenneth A. Jamerson M.D. | Hypertension control in high risk patients | V9818 |
| 98/05/08 | ¬IZªL | ±qªk«ß·sµø¬É½Í¥Í©R»PÂåÀøªk«ß | V9819 |
| 98/05/29 | ³¯ºaºÖ¥D¥ô | °©ÃPªvÀøªº·s¶i®i | V9822 |
| 98/06/05 | ¶À¤ô©[±Ð±Â | The Development of radiofrequency catheter ablation of cardiac arrhythmias implication for becoming a physician seientist | V9824 |
| 98/06/12 | §õ¤¸ÄQ¥D¥ô | §Úªº¥~¬ì¥Í²P»PªÍŦ²¾´Ó | V9825 |
| 98/06/19 | §dÂE©úÂå®v | Bridging bench to clinic: roles of glia for the therapy of neurologic diseases | V9826 |
| 98/06/26 | ·¨§Ó°¶Âå®v | ÂåÀø¹Î¶¤¦X§@°V½m | V9827 |
| 98/07/03 | ³\¥Ã²»¥D¥ô | ¥þ°|Á{§É¯f²z®×¨ÒÁp¦X°Q½×·| | V9828 |
| 98/07/10 | ¬x¦¨§Ó±Ð±Â | ¦µo«¬¥¢´¼¯gªº°ò¦]¶EÂ_»P¿ò¶Ç¿Ô¸ß | V9829 |
| 98/07/17 | ½²¦æ¿«°Æ°|ªø | °ê¤º¤Î°ê»ÚªÅ¤¤ºò«æÂåÀø±Ï´© | V9830 |
| 98/07/24 | ³\´fùÚ¥D¥ô | Linking Metabolic Momory and CV disease: What have we learned? | V9831 |
| 98/07/31 | ¶À«T¶¯¥D¥ô | ÂåÀø«~½è§ï¶i®×¨Ò¬ã°Q | V9832 |
| 98/08/14 | ¸«Û§B§½ªø | Âå°|¬°°ò¦ªº°·±dºÞ²zµ¦²¤ | V9834 |
| 98/08/21 | ¤ý¤h©¾Âå®v | ¿é¦åÂå¾Ç | V9835 |
§ó·s¤é´Á:2009/11/04